PD-1 Clinical Trial
Official title:
Clinical Study on Multidimensional Prevention of Sintilimab Induced irAEs Based on GEP Pattern Recognition
In recent years, immunotherapy has become one of the important treatments for malignant tumors. Among them, PD-1 inhibitors have been widely used in clinical practice, and have shown a significant survival benefits in many patients. However, the incidence of immune-related adverse reactions (irAEs) of PD-1 inhibitors is relatively high, and severe cases can even threaten patients's life. At present, irAEs have become a bottleneck and it is urgent to establish a prevention strategy for the prediction of irAEs. In this study, we intends to use Sintilimab as the research drug. A prospective cohort study was carried out. Part of the sample which was used as a training set would be detected for producing a time-series multi-dimensional data such as differential genes, metabolites and immune factors. Then gene expression programming (GEP) was used to explore the irAEs recognition model. Then, based on this recognition model, internal verification ( part of samples from the center 1 ) and external verification ( part of samples from the center 2 and center 3 samples) are carried out to accurately predict the high-risk population of irAEs and realize the early-stage warning of Sintilimab induced- irAEs.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
| Recruiting |
NCT06250894 -
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
|
Phase 2 | |
| Recruiting |
NCT04778956 -
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
|
Phase 3 | |
| Not yet recruiting |
NCT05741021 -
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Not yet recruiting |
NCT04284202 -
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT04615988 -
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
|
||
| Active, not recruiting |
NCT04906044 -
Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer
|
Phase 1 | |
| Recruiting |
NCT05508399 -
Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma
|
||
| Not yet recruiting |
NCT04690036 -
PD-1 Antibody for Reactive EBV After BMT
|
Early Phase 1 | |
| Recruiting |
NCT05980715 -
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
|
Phase 3 | |
| Recruiting |
NCT04191252 -
Genetic Mutation in Epithelial Ovarian Cancer
|
||
| Recruiting |
NCT04191226 -
Genetic Mutation in Recurrent Cervical Cancer
|
||
| Not yet recruiting |
NCT04061928 -
Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05979740 -
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
|
Phase 2 | |
| Recruiting |
NCT05980702 -
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
|
Phase 2 | |
| Not yet recruiting |
NCT04814069 -
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinomaļ¼The POTENTIAL Study
|
Phase 2 |